

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Alebund Pharmaceuticals (Jiangsu) Limited

禮邦醫藥(江蘇)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 09637)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, AUGUST 14, 2026

Reference is made to the circular of Alebund Pharmaceuticals (Jiangsu) Limited (the “**Company**”) dated July 24, 2026 (the “**Circular**”) in relation to the extraordinary general meeting (the “**EGM**”) of the Company. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The proposed resolutions as set out in the notice of the EGM dated July 24, 2026 (the “**Notice**”) were voted on by poll.

All Directors attended the EGM in person or by electronic means.

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that at the EGM held on Friday, August 14, 2026, the proposed ordinary resolution and special resolutions as set out in the Notice were duly passed by the Shareholders by way of poll. The poll results of the EGM are as follows:

ORDINARY RESOLUTION		NUMBER OF VALID VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the proposed appointment of auditor.	143,960,261 (92.4159%)	19,100 (0.0123%)	11,795,028 (7.5719%)
SPECIAL RESOLUTIONS		FOR	AGAINST	ABSTAIN
2.	To consider and approve the proposed granting of general mandate to issue Shares.	140,112,950 (89.9461%)	3,866,411 (2.4821%)	11,795,028 (7.5719%)
3.	To consider and approve the proposed granting of general mandate to repurchase H Shares.	143,979,361 (92.4281%)	0 (0.0000%)	11,795,028 (7.5719%)

Notes:

- (a) As more than half of the votes were cast in favor of the resolution numbered 1, the resolution was duly passed as ordinary resolution.
- (b) As more than two-thirds of the votes were cast in favor of the resolutions numbered 2 and 3, the resolutions were duly passed as special resolutions.
- (c) As at the date of the EGM, the total number of Shares in issue was 348,365,531 Shares (of which 235,635,489 were H Shares and 112,730,042 were Unlisted Shares). The total number of Shares entitling the holders to attend and vote on the resolutions proposed at the EGM was 348,365,531 Shares.
- (d) As at the date of the EGM, the Company did not have any Treasury Shares or repurchased Shares pending cancellation.
- (e) There was no restriction on any Shareholders casting votes on the resolutions proposed at the EGM.
- (f) There were no Shares entitling the holders to attend and abstain from voting in favor of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules and no Shareholders were required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM.
- (g) None of the Shareholders stated their intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the EGM.
- (h) The Company's H Share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote taking at the EGM.
- (i) The full text of the resolutions referred to above appears in the Notice.

By order of the Board
Alebund Pharmaceuticals (Jiangsu) Limited
Dr. Gavin Guoyao Xia
*Chairman of the Board, executive Director and
Chief Executive Officer*

Hong Kong, August 14, 2026

As of the date of this announcement, the Board comprises (i) Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading as executive Directors; (ii) Dr. Lu An as a non-executive Director; and (iii) Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai as independent non-executive Directors.